KB 001 - Keystone Bio
Alternative Names: KB-001 - Keystone Bio; KB-001 MabLatest Information Update: 15 Sep 2021
At a glance
- Originator Keystone Bio
- Class Anti-inflammatories; Antibacterials; Monoclonal antibodies
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Periodontal disorders
Most Recent Events
- 26 Jul 2021 Interim immunogenicity data from a clinical trial in periodontal disorders presented at the Alzheimer's Association International Conference 2021 (AAIC-2021)
- 26 Jul 2021 Pharmacodynamics data from a preclinical trial in periodontal disorders presented at the Alzheimer's Association International Conference 2021 (AAIC-2021)
- 01 Jul 2021 Clinical trials in Periodontal disorders (Prevention) in USA (PO) (Keystone Bio website, September 2021)